



News | September 17, 2008

## Quigley Announces Positive Follow Up Study Of Poultry With Infectious Bronchitis: Results Demonstrate Longer Duration Of Protection From Infectious Bronchitis And Reduction Of Clinical Signs In Chickens

Doylestown, PA - The Quigley Corporation, [www.quigleyco.com](http://www.quigleyco.com), announced successful results from a follow up study conducted by its wholly owned subsidiary, Quigley Pharma, [www.QuigleyPharma.com](http://www.QuigleyPharma.com), with its veterinary anti-viral compound QR448(a). The Study was designed to determine the duration of anti-viral effect of QR448(a) against Infectious Bronchitis Virus (IBV) in commercial broiler chickens, a consumer meat type bird.

The data from the study indicate that 1 day old commercial broilers, when treated with QR448(a) were protected 50-100% of the time from the weakening clinical pathogenic effects of IBV for up to 4 days compared to 0-20% of the time in un-treated birds. The reduction or absence of clinical signs observed, likely indicates little or no damage to upper respiratory tract tissue which is extremely significant because damage to this area caused by untreated IBV infections leaves birds exposed to potentially deadly secondary infections, such as those caused by *Escherichia coli*, which can be responsible for significant financial losses to poultry producers. Clinical pathogenic signs are defined as, watery eyes, mucus in nares, and tracheal rales.

Losses are calculated as a result of lower weight gains and feed efficiency in broilers, condemnation of poultry products at processing plants, lowered production and quality of eggs in layers and breeders, mortality, clean-up costs and disruption to operations.

As previously announced, the Company sought and gained advice from commercial market and research leaders from within the poultry industry to establish a development program built on previous positive data and future performance criteria that will best verify the commercial viability and optimize the potential prospects for joint development of the QR448(a) candidate.

Based upon the positive results of this study and the expressed increasing need for additional products to combat IBV by poultry industry leaders, the Company expects to further investigate the effectiveness of the compound.

Dr. Richard Rosenbloom Executive Vice President and COO of Quigley Pharma stated: "We are encouraged by the consistency of these data in addition to past results which clearly indicate that the compound effectively reduces the clinical signs and presence of IBV in SPF (egg layer type) as well as commercial broiler (meat type) chickens. Additionally promising is the 4 day duration of protection and possibility of once per 4 day dose, which could prevent the birds from succumbing to more significant infections."

Dr. Mark Jackwood, Professor, Department of Population Health, College of Veterinary Medicine, University of Georgia stated: "In the hundreds of times we have challenged chickens with IBV and then treated them with the QR448(a) compound, the reduction of clinical signs in the treated birds has been truly dramatic. It is also important to remember that the amount of live virus in the treated birds could be much lower since our test detects both live and dead viruses. Also, an additional benefit of these viruses in the trachea could be to induce a natural immune response, adding another level of protection against the disease beyond the effective duration of the compound."

### About the Study:

The study was conducted by Dr. Mark Jackwood Professor, Department of Population Health, College of Veterinary Medicine, University of Georgia who reported:

- One day old commercial broilers in groups of 10 birds were spray treated with 1ml of a 1:20 dilution of QR448(a) per bird then challenged with  $1 \times 10^4$  (to the 4 power) EID (for 50%) of pathogenic IBV (Mass type) at 2 hrs, 4 hrs, 6 hrs, 1 day 2 days, 4 days and 7 days post QR448(a) treatment. Non- treated control birds were also challenged at the same time periods.
- Birds challenged with IBV and treated with QR448(a) within 4 days exhibited a 50-100% degree of protection from clinical signs of infection. This is in contrast to birds that were challenged and not treated with QR448(a) where the protection based on clinical signs ranged from 0-20%.
- Tracheal swabbing detected challenge virus in all of the challenged birds not treated with QR448(a). Lower levels of virus (but not statistically significant) were detected in the birds treated with QR448(a), indicating that there was no protection from infection although the reduction or absence of clinical signs in the QR448(a) treated groups likely indicates little or no damage to the upper respiratory tract.
- Challenge virus detection with mild or no clinical signs in the QR448(a) treated birds is similar to results from previous studies with QR448(a) -- although in this study we did not see a significant drop in the amount of virus in the trachea.
- Serological and histological data is pending but is not expected to negatively impact these results.
- In summary, QR448(a) protected broiler chickens for up to 4 days post-treatment from clinical signs of the disease (but not from

Subsequent to the positive results of this trial, the Company began an investigation of the effects of the QR448(a) candidate on the transmission of virus in a larger population of commercial broilers in housing conditions more representative of commercial breeding.

The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will issue an investigational new animal drug number or allow this compound to be marketed for IBV. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

*SOURCE: The Quigley Corporation*

## Like what you are reading?

Sign up for our free newsletter



I agree to the [Terms](#) and [Privacy Statement](#)

### Newsletter Signup



Get the latest industry news, insights, and analysis delivered to your inbox.

### Join your peers

I agree to the [Terms](#) and [Privacy Statement](#).

## YOU MAY ALSO LIKE...

### [Quigley's Broad Spectrum Anti-Viral QR-441\(a\) Shown To Be Effective Against Two Problematic Pathogens To The Poultry Industry](#)

Quigley Pharma, a wholly owned subsidiary of The Quigley Corporation announced positive results from a study evaluating its anti-viral compound QR-441(a) in embryonating egg and VERO E6 cell test...

### [Intervet/Schering-Plough Animal Health's New INNOVAX Poultry Vaccine Range Now Available In Latin America](#)

Intervet/Schering-Plough Animal Health, the global leader in animal health solutions, announces recently that its innovative recombinant INNOVAX poultry vaccine range has been introduced in markets...

### [Pre-Harvest Food Safety: Research At International Poultry Scientific Forum](#)

Federal U.S. food safety surveillance data in recent years shows significant progress by the poultry and red meat industries in reducing foodborne pathogens. Nonetheless, notes Doug Smith, Ph.D.,...

### [Intervet/Schering-Plough Animal Health Sponsors Peer-Reviewed Website On Chicken Anemia Virus](#)

A peer-reviewed website about chicken infectious anemia has been launched under the sponsorship of Intervet/Schering-Plough Animal Health.

### [America's Largest Chicken Association Rolls Out Industry-Wide Standards For Broiler Chicken Welfare](#)

The National Chicken Council (NCC), the United States' oldest and largest national association representing the U.S. broiler chicken industry (chickens raised for meat), today rolled out a set of...

### [Commercial Poultry Lack Genetic Diversity, Are Vulnerable To Avian Flu And Other Threats](#)

### [Avian Influenza Tests Complete On Maryland Resident Wild Mallard Ducks](#)

### [USDA Reports Salmonella Cases Down Nearly Half; Glickman Credits HACCP](#)

### [New Vaccine Developed For Newcastle Disease](#)

This website uses cookies to ensure you get the best experience on our website. [Learn more](#)

[Perdue Invests Millions In Higher Welfare Stunning And Processing](#)

---

[Scientifically Validated Results To Raise Poultry Production Profitability](#)

---

---

## About Us

[Contact Meat and Poultry](#)

[Editorial Submission Guidelines](#)

Copyright © 1996-2020 [VertMarkets, Inc.](#) All Rights Reserved. [Terms of Use](#). [Privacy Statement](#). [Subscriber Request Form](#).